Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Xofigo Patient Case Studies

Bayer has collaborated with healthcare professionals across the multidisciplinary team to develop a series of patient case studies. These case studies were developed as a promotional educational resource and share real-world experience from experts on the treatment and management of their patients with metastatic castration-resistant prostate cancer (mCRPC). Each case study covers the whole patient journey, from initial diagnosis and treatment decisions to outcomes and tolerability.

 

These case studies share a range of different patient profiles including different ages, treatment histories, concomitant medications and outcomes to help visualise and identify eligible mCRPC patients who may be suitable for treatment with Xofigo.

 

Xofigo Patient Case Study: A Radiographer perspective

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

By Miss Jo Weekes, Consultant Radiographer, The Royal Wolverhampton NHS Trust, Wolverhampton

 

Patient: 83 years old when diagnosed with advanced prostate cancer who was ARi-ineligible due to previous cardiovascular disease

 

Treatment goal: Slow down the decline of quality of life and improve overall survival vs placebo, whilst reducing his symptoms due to the bone-metastases.1 3rd line treatment with Xofigo

This patient case study is initiated and funded by Bayer plc. No patient identifiable data or photos of patients are shared within these case studies and the appropriate consent from the patients was collected by the HCP prior to development. Individual responses and experiences to medicinal products may vary.

Speakers

Miss Jo Weekes

Miss Jo Weekes

Miss Jo Weekes: Consultant Radiographer:

Qualifications: DCR(R), DRI, MSc (oxon)

Address: The Royal Wolverhampton NHS Trust

 

  • Appointed as the first Consultant Radiographer in Nuclear Medicine in the UK. 

  • Chair of the Nuclear Medicine and Molecular Imaging Advisory Group (Society of Radiographers (UK)).

  • Member of the Radiographers, Technologist and Nurses Committee (British Nuclear Medicine Society)

  • Member of UK MRT (Molecular Radiotherapy) Consortium Steering Group

  • Jo has lectured at the European Association of Nuclear Medicine in Barcelona, BNMS and regional meetings

  • Jo has also lectured at Oxford University in nuclear medicine (FRCR Part 1 course)

  • Main areas of interest are MRT and patient treatment pathways

    • One of her aims is to derive pathways for future radiographers / technologists to gain accreditation by education and development of career pathways, deriving a pathway for future radiographers / technologists to gain the accreditation needed to replicate her success in their own units

    • Updating, training (medics, radiographers, technologists and assistants) in all aspects of nuclear medicine from protocol derivation to radiation protection issues especially in the field of therapeutic nuclear medicine.

    • Taking lead and managing Molecular Radiotherapy Therapy planning and treatment clinics. 

Click below to view other Xofigo Patient Case Studies:

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS
REFERENCES

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.